Zymeworks (ZYME)
Zymeworks on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
5.6M
Short interest
settlement 2026-10-15
4.4
Days to cover
-1.2 days vs prior
75.2%
Short share of volume
2026-11-02
1,120
Fails to deliver
settlement 2026-10-06
Thu 5 Nov
Next earnings
estimated date
-$358K
Insider flow, 90 days
0 buys, 1 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in ZYME is 5,577,540 shares, up 638,468 shares over the last month. Over the last 48 readings it ranged from 3,603,765 shares (31 December 2025) to 8,541,535 shares (14 November 2025). At the reported average volume of 1.3M shares a day that is 4.4 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/zyme" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 5,577,540 | +5.4% | 1,279,838 | 4.36 |
| 2026-09-30 | 5,291,136 | +7.1% | 953,928 | 5.55 |
| 2026-09-15 | 4,939,072 | +4.5% | 619,914 | 7.97 |
| 2026-08-31 | 4,724,831 | +4.1% | 827,575 | 5.71 |
| 2026-08-14 | 4,538,353 | +10.5% | 533,925 | 8.50 |
| 2026-07-31 | 4,106,590 | +0.1% | 376,796 | 10.90 |
| 2026-07-15 | 4,102,257 | -6.0% | 542,279 | 7.56 |
| 2026-06-30 | 4,364,318 | -2.7% | 704,780 | 6.19 |
| 2026-06-15 | 4,485,642 | -0.9% | 804,667 | 5.57 |
| 2026-05-29 | 4,527,668 | +1.3% | 594,680 | 7.61 |
| 2026-05-15 | 4,470,973 | -3.8% | 673,335 | 6.64 |
| 2026-04-30 | 4,648,225 | -0.1% | 553,518 | 8.40 |
| 2026-04-15 | 4,652,176 | +4.3% | 664,924 | 7.00 |
| 2026-03-31 | 4,461,520 | +9.4% | 553,578 | 8.06 |
| 2026-03-13 | 4,078,338 | -1.4% | 969,195 | 4.21 |
| 2026-02-27 | 4,135,418 | +4.1% | 457,960 | 9.03 |
| 2026-02-13 | 3,973,308 | +5.2% | 550,233 | 7.22 |
| 2026-01-30 | 3,777,909 | -1.2% | 642,258 | 5.88 |
| 2026-01-15 | 3,823,322 | +6.1% | 1,280,941 | 2.98 |
| 2025-12-31 | 3,603,765 | -8.5% | 559,387 | 6.44 |
| 2025-12-15 | 3,938,970 | -29.8% | 693,921 | 5.68 |
| 2025-11-28 | 5,609,170 | -34.3% | 2,881,037 | 1.95 |
| 2025-11-14 | 8,541,535 | +13.4% | 1,073,347 | 7.96 |
| 2025-10-31 | 7,531,090 | +6.9% | 996,465 | 7.56 |
| 2025-10-15 | 7,047,624 | +1.9% | 713,177 | 9.88 |
| 2025-09-30 | 6,918,885 | -3.3% | 636,013 | 10.88 |
| 2025-09-15 | 7,156,267 | +3.9% | 525,495 | 13.62 |
| 2025-08-29 | 6,885,888 | +1.1% | 390,459 | 17.64 |
| 2025-08-15 | 6,807,564 | +0.0% | 520,341 | 13.08 |
| 2025-07-31 | 6,806,921 | -0.9% | 409,137 | 16.64 |
| 2025-07-15 | 6,868,563 | -0.8% | 378,522 | 18.15 |
| 2025-06-30 | 6,925,863 | +0.6% | 600,788 | 11.53 |
| 2025-06-13 | 6,883,488 | -4.3% | 423,298 | 16.26 |
| 2025-05-30 | 7,193,207 | +5.9% | 415,640 | 17.31 |
| 2025-05-15 | 6,791,821 | +2.7% | 469,184 | 14.48 |
| 2025-04-30 | 6,615,244 | +1.8% | 516,389 | 12.81 |
| 2025-04-15 | 6,496,685 | +20.1% | 1,057,087 | 6.15 |
| 2025-03-31 | 5,406,929 | -0.2% | 581,755 | 9.29 |
| 2025-03-14 | 5,415,327 | +36.6% | 914,773 | 5.92 |
| 2025-02-28 | 3,963,020 | +3.3% | 414,856 | 9.55 |
| 2025-02-14 | 3,837,127 | -12.4% | 372,533 | 10.30 |
| 2025-01-31 | 4,380,063 | -3.9% | 308,014 | 14.22 |
| 2025-01-15 | 4,556,864 | +9.8% | 554,850 | 8.21 |
| 2024-12-31 | 4,148,390 | -4.4% | 581,981 | 7.13 |
| 2024-12-13 | 4,338,660 | -6.3% | 418,072 | 10.38 |
| 2024-11-29 | 4,632,532 | +10.1% | 400,192 | 11.58 |
| 2024-11-15 | 4,208,640 | -10.5% | 679,405 | 6.19 |
| 2024-10-31 | 4,700,126 | +12.9% | 403,439 | 11.65 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of ZYME volume is 75.2%, up 27.4 points over the last five sessions. Over the last 30 readings it ranged from 35.0% (30 September 2026) to 75.2% (2 November 2026). The latest reading sits at the top of that range. The latest reading is 19.0 points above the 30-session average of 56.2%, on 298K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 225K | 298K | 75.2% | 0 |
| 2026-10-30 | 62K | 114K | 54.2% | 0 |
| 2026-10-29 | 83K | 219K | 38.0% | 100 |
| 2026-10-28 | 84K | 239K | 35.1% | 0 |
| 2026-10-27 | 135K | 233K | 58.0% | 0 |
| 2026-10-26 | 111K | 232K | 47.8% | 0 |
| 2026-10-23 | 195K | 322K | 60.6% | 0 |
| 2026-10-22 | 114K | 203K | 56.2% | 0 |
| 2026-10-21 | 245K | 365K | 67.2% | 0 |
| 2026-10-20 | 543K | 791K | 68.7% | 0 |
| 2026-10-19 | 95K | 139K | 68.5% | 91 |
| 2026-10-16 | 93K | 147K | 63.7% | 0 |
| 2026-10-15 | 83K | 149K | 55.9% | 0 |
| 2026-10-14 | 85K | 122K | 69.2% | 0 |
| 2026-10-13 | 44K | 80K | 55.4% | 0 |
| 2026-10-12 | 60K | 104K | 57.6% | 0 |
| 2026-10-09 | 106K | 158K | 67.2% | 0 |
| 2026-10-08 | 149K | 239K | 62.2% | 0 |
| 2026-10-07 | 162K | 228K | 71.0% | 0 |
| 2026-10-06 | 88K | 211K | 41.7% | 0 |
| 2026-10-05 | 103K | 158K | 65.3% | 0 |
| 2026-10-02 | 110K | 212K | 52.0% | 0 |
| 2026-10-01 | 78K | 139K | 56.5% | 0 |
| 2026-09-30 | 83K | 237K | 35.0% | 0 |
| 2026-09-29 | 91K | 211K | 43.4% | 0 |
| 2026-09-28 | 84K | 186K | 45.3% | 0 |
| 2026-09-25 | 104K | 213K | 48.7% | 0 |
| 2026-09-24 | 193K | 329K | 58.6% | 0 |
| 2026-09-23 | 139K | 241K | 57.8% | 0 |
| 2026-09-22 | 81K | 161K | 50.3% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 6 October 2026, the fails-to-deliver balance in ZYME is 1,120 shares, down 16,864 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (12 August 2026) to 17,984 shares (21 September 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-06 | 1,120 | $26.21 | $29K |
| 2026-09-21 | 17,984 | $26.57 | $478K |
| 2026-09-18 | 1,155 | $27.48 | $32K |
| 2026-08-27 | 56 | $29.31 | $2K |
| 2026-08-25 | 43 | $28.77 | $1K |
| 2026-08-24 | 79 | $28.67 | $2K |
| 2026-08-19 | 6 | $26.07 | $156 |
| 2026-08-14 | 282 | $25.76 | $7K |
| 2026-08-12 | 2 | $24.32 | $49 |
| 2026-08-11 | 905 | $24.16 | $22K |
| 2026-08-06 | 597 | $23.50 | $14K |
| 2026-08-05 | 17 | $22.79 | $387 |
| 2026-08-03 | 30 | $21.94 | $658 |
| 2026-07-23 | 3,354 | $23.36 | $78K |
| 2026-07-22 | 4,899 | $24.05 | $118K |
| 2026-07-20 | 6,803 | $24.19 | $165K |
| 2026-07-17 | 71 | $24.19 | $2K |
| 2026-07-16 | 73 | $24.66 | $2K |
| 2026-07-09 | 1,965 | $26.65 | $52K |
| 2026-06-18 | 72 | $23.14 | $2K |
| 2026-06-12 | 12,377 | $22.97 | $284K |
| 2026-06-11 | 1,005 | $22.85 | $23K |
| 2026-06-05 | 5,430 | $25.10 | $136K |
| 2026-06-04 | 71 | $24.35 | $2K |
| 2026-06-03 | 3,678 | $24.11 | $89K |
| 2026-05-26 | 88 | $25.61 | $2K |
| 2026-05-20 | 117 | $24.40 | $3K |
| 2026-05-19 | 4,700 | $24.43 | $115K |
| 2026-05-14 | 309 | $24.57 | $8K |
| 2026-05-01 | 47 | $27.54 | $1K |
Insider trades
SEC Form 4, newest first. JSONInsiders at ZYME reported 1 open-market sell worth $358K in the last 90 days and no open-market buys. Latest filing: Schayowitz Adam (EVP, Head of R&D) on 2026-10-09.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-09 | Schayowitz Adam | EVP, Head of R&D | Sell | 14K | $25.85 | $358K | 23K |
| 2026-10-09 | Schayowitz Adam | EVP, Head of R&D | Exercise or conversion | 37K | $0.00 | $0 | 37K |
| 2026-07-06 | Hollywood Mark | EVP & Chief Operating Officer | Grant | 939 | $22.22 | $21K | 134K |
| 2026-01-12 | Smith Jeffrey T L | EVP & Chief Medical Officer | Sell | 9K | $22.67 | $211K | 27K |
| 2026-01-12 | Smith Jeffrey T L | EVP & Chief Medical Officer | Exercise or conversion | 18K | $0.00 | $0 | 36K |
| 2026-01-12 | Moore Paul Andrew | Chief Scientific Officer | Sell | 10K | $22.67 | $217K | 48K |
| 2026-01-12 | Moore Paul Andrew | Chief Scientific Officer | Exercise or conversion | 18K | $0.00 | $0 | 58K |
| 2026-01-12 | Galbraith Kenneth | Chair & CEO | Sell | 30K | $22.67 | $690K | 227K |
| 2026-01-12 | Galbraith Kenneth | Chair & CEO | Exercise or conversion | 64K | $0.00 | $0 | 257K |
| 2026-01-12 | Hollywood Mark | EVP & Chief Operating Officer | Sell | 6K | $22.67 | $139K | 133K |
| 2026-01-12 | Hollywood Mark | EVP & Chief Operating Officer | Exercise or conversion | 18K | $0.00 | $0 | 139K |
| 2026-01-06 | PATTERSON LEONE D | EVP, Chief Bus & Fin Officer | Grant | 459 | $10.55 | $5K | 459 |
| 2026-01-05 | Smith Jeffrey T L | EVP & Chief Medical Officer | Sell | 11K | $25.10 | $264K | 18K |
| 2026-01-05 | Smith Jeffrey T L | EVP & Chief Medical Officer | Exercise or conversion | 20K | $0.00 | $0 | 29K |
| 2026-01-05 | Moore Paul Andrew | Chief Scientific Officer | Sell | 11K | $25.10 | $272K | 40K |
| 2026-01-05 | Moore Paul Andrew | Chief Scientific Officer | Exercise or conversion | 20K | $0.00 | $0 | 51K |
| 2026-01-05 | Moore Paul Andrew | Chief Scientific Officer | Sell | 9K | $25.10 | $233K | 31K |
| 2026-01-05 | Moore Paul Andrew | Chief Scientific Officer | Exercise or conversion | 17K | $0.00 | $0 | 41K |
| 2026-01-05 | Galbraith Kenneth | Chair & CEO | Sell | 32K | $25.10 | $795K | 193K |
| 2026-01-05 | Galbraith Kenneth | Chair & CEO | Exercise or conversion | 67K | $0.00 | $0 | 225K |
| 2026-01-05 | Galbraith Kenneth | Chair & CEO | Sell | 23K | $25.10 | $569K | 158K |
| 2026-01-05 | Galbraith Kenneth | Chair & CEO | Exercise or conversion | 48K | $0.00 | $0 | 181K |
| 2025-12-22 | Galbraith Kenneth | Chair & CEO | Sell | 48K | $27.02 | $1.3M | 133K |
| 2025-12-22 | Galbraith Kenneth | Chair & CEO | Exercise or conversion | 100K | $0.00 | $0 | 181K |
| 2025-08-12 | Ciongoli Gregory Austin | Director | Grant | 415K | $12.02 | $5.0M | 489K |
| 2025-06-26 | NODELMAN OLEG | Director,TenPercentOwner | Tax withholding | 41 | $12.71 | $521 | 23.0M |
| 2025-06-26 | NODELMAN OLEG | Director,TenPercentOwner | Exercise (in or at the money) | 5.1M | $0.00 | $0 | 23.0M |
| 2025-06-26 | EcoR1 Capital, LLC | Director, 10% owner | Tax withholding | 41 | $12.71 | $521 | 23.0M |
| 2025-06-26 | EcoR1 Capital, LLC | Director, 10% owner | Exercise (in or at the money) | 5.1M | $0.00 | $509 | 23.0M |
| 2025-05-19 | EcoR1 Capital, LLC | Director,TenPercentOwner | Buy | 6K | $11.78 | $70K | 17.9M |
| 2025-05-15 | EcoR1 Capital, LLC | Director,TenPercentOwner | Buy | 50K | $11.43 | $566K | 17.9M |
| 2025-04-17 | EcoR1 Capital, LLC | Director,TenPercentOwner | Buy | 55K | $11.52 | $631K | 17.8M |
| 2025-04-16 | EcoR1 Capital, LLC | Director,TenPercentOwner | Buy | 74K | $11.16 | $825K | 17.8M |
| 2025-04-04 | NODELMAN OLEG | Director,TenPercentOwner | Buy | 196K | $11.17 | $2.2M | 17.7M |
| 2025-04-03 | NODELMAN OLEG | Director,TenPercentOwner | Buy | 121K | $11.84 | $1.4M | 17.5M |
| 2025-04-02 | EcoR1 Capital, LLC | Director,TenPercentOwner | Buy | 74K | $11.85 | $881K | 17.4M |
| 2025-04-01 | EcoR1 Capital, LLC | Director,TenPercentOwner | Buy | 49K | $11.60 | $564K | 17.3M |
| 2025-03-31 | EcoR1 Capital, LLC | Director,TenPercentOwner | Buy | 4K | $11.75 | $52K | 17.3M |
| 2025-03-26 | EcoR1 Capital, LLC | Director,TenPercentOwner | Buy | 44K | $12.24 | $537K | 17.3M |
| 2025-03-25 | EcoR1 Capital, LLC | Director,TenPercentOwner | Buy | 54K | $12.91 | $691K | 17.2M |
| 2025-03-24 | EcoR1 Capital, LLC | Director,TenPercentOwner | Buy | 23K | $13.08 | $297K | 17.2M |
| 2025-03-21 | EcoR1 Capital, LLC | Director,TenPercentOwner | Buy | 31K | $12.78 | $397K | 17.1M |
| 2025-03-20 | EcoR1 Capital, LLC | Director,TenPercentOwner | Buy | 73K | $12.93 | $950K | 17.1M |
| 2025-03-19 | EcoR1 Capital, LLC | Director,TenPercentOwner | Buy | 58K | $12.64 | $737K | 17.0M |
| 2025-03-18 | EcoR1 Capital, LLC | Director,TenPercentOwner | Buy | 114K | $12.65 | $1.4M | 17.0M |
| 2025-03-17 | EcoR1 Capital, LLC | Director,TenPercentOwner | Buy | 56K | $12.23 | $688K | 16.9M |
| 2025-03-13 | NODELMAN OLEG | Director,TenPercentOwner | Buy | 468K | $12.48 | $5.8M | 16.8M |
| 2025-03-12 | NODELMAN OLEG | Director,TenPercentOwner | Buy | 293K | $12.25 | $3.6M | 16.3M |
| 2025-03-11 | NODELMAN OLEG | Director,TenPercentOwner | Buy | 321K | $11.49 | $3.7M | 16.0M |
| 2025-01-17 | EcoR1 Capital, LLC | Director,TenPercentOwner | Buy | 20K | $13.87 | $274K | 15.7M |
| 2025-01-16 | EcoR1 Capital, LLC | Director,TenPercentOwner | Buy | 122K | $13.89 | $1.7M | 15.7M |
| 2025-01-15 | EcoR1 Capital, LLC | Director,TenPercentOwner | Buy | 39K | $14.01 | $547K | 15.6M |
| 2025-01-14 | EcoR1 Capital, LLC | Director,TenPercentOwner | Buy | 55K | $13.56 | $739K | 15.5M |
| 2025-01-13 | EcoR1 Capital, LLC | Director,TenPercentOwner | Buy | 74K | $13.39 | $993K | 15.5M |
| 2025-01-10 | EcoR1 Capital, LLC | Director,TenPercentOwner | Buy | 204K | $13.13 | $2.7M | 15.4M |
| 2025-01-08 | EcoR1 Capital, LLC | Director,TenPercentOwner | Buy | 21K | $14.07 | $296K | 15.2M |
| 2025-01-06 | Smith Jeffrey T L | EVP & Chief Medical Officer | Sell | 11K | $14.92 | $166K | 9K |
| 2025-01-06 | Smith Jeffrey T L | EVP & Chief Medical Officer | Exercise or conversion | 20K | $0.00 | $0 | 20K |
| 2025-01-06 | Galbraith Kenneth | Chair & CEO | Exercise or conversion | 48K | $0.00 | $0 | 71K |
| 2025-01-06 | Galbraith Kenneth | Chair & CEO | Sell | 33K | $14.92 | $498K | 81K |
| 2025-01-06 | Galbraith Kenneth | Chair & CEO | Exercise or conversion | 67K | $0.00 | $0 | 114K |
| 2025-01-06 | Galbraith Kenneth | Chair & CEO | Sell | 24K | $14.92 | $356K | 48K |
| 2025-01-06 | Moore Paul Andrew | Chief Scientific Officer | Exercise or conversion | 17K | $0.00 | $0 | 25K |
| 2025-01-06 | Moore Paul Andrew | Chief Scientific Officer | Sell | 10K | $14.92 | $146K | 15K |
| 2025-01-06 | Moore Paul Andrew | Chief Scientific Officer | Sell | 11K | $14.92 | $170K | 23K |
| 2025-01-06 | Moore Paul Andrew | Chief Scientific Officer | Exercise or conversion | 20K | $0.00 | $0 | 35K |
| 2025-01-02 | EcoR1 Capital, LLC | Director,TenPercentOwner | Buy | 158K | $14.78 | $2.3M | 15.2M |
| 2024-12-31 | EcoR1 Capital, LLC | Director,TenPercentOwner | Buy | 147K | $14.57 | $2.1M | 15.0M |
| 2024-12-30 | EcoR1 Capital, LLC | Director,TenPercentOwner | Buy | 59K | $14.47 | $854K | 14.9M |
| 2024-12-27 | EcoR1 Capital, LLC | Director,TenPercentOwner | Buy | 102K | $14.49 | $1.5M | 14.8M |
| 2024-12-26 | EcoR1 Capital, LLC | Director,TenPercentOwner | Buy | 17K | $14.38 | $240K | 14.7M |
| 2024-12-24 | EcoR1 Capital, LLC | Director,TenPercentOwner | Buy | 12K | $14.12 | $169K | 14.7M |
| 2024-12-23 | EcoR1 Capital, LLC | Director,TenPercentOwner | Buy | 252K | $14.25 | $3.6M | 14.7M |
| 2024-12-20 | EcoR1 Capital, LLC | Director,TenPercentOwner | Buy | 704K | $14.08 | $9.9M | 14.4M |
| 2024-12-19 | EcoR1 Capital, LLC | Director,TenPercentOwner | Buy | 299K | $13.53 | $4.0M | 13.7M |
| 2024-01-08 | Moore Paul Andrew | Chief Scientific Officer | Sell | 2K | $11.22 | $26K | 7K |
| 2024-01-08 | Astle Christopher | SVP & Chief Financial Officer | Sell | 1K | $11.22 | $16K | 7K |
| 2024-01-08 | Galbraith Kenneth | Chair & CEO | Sell | 6K | $11.22 | $64K | 24K |
| 2024-01-05 | Moore Paul Andrew | Chief Scientific Officer | Sell | 7K | $10.65 | $79K | 10K |
| 2024-01-05 | Moore Paul Andrew | Chief Scientific Officer | Exercise or conversion | 17K | $0.00 | $0 | 17K |
| 2024-01-05 | Astle Christopher | SVP & Chief Financial Officer | Sell | 5K | $10.65 | $49K | 8K |
| 2024-01-05 | Astle Christopher | SVP & Chief Financial Officer | Exercise or conversion | 11K | $0.00 | $0 | 12K |
| 2024-01-05 | Galbraith Kenneth | Chair & CEO | Sell | 18K | $10.65 | $194K | 29K |
| 2024-01-05 | Galbraith Kenneth | Chair & CEO | Exercise or conversion | 48K | $0.00 | $0 | 48K |
| 2023-12-11 | Astle Christopher | SVP & Chief Financial Officer | Exercise or conversion | 2K | $0.00 | $0 | 3K |
| 2023-12-11 | Astle Christopher | SVP & Chief Financial Officer | Sell | 886 | $9.13 | $8K | 2K |
| 2023-06-16 | EcoR1 Capital, LLC | TenPercentOwner | Buy | 3.4M | $8.12 | $27.2M | 13.4M |
| 2023-03-28 | EcoR1 Capital, LLC | TenPercentOwner | Buy | 200K | $8.00 | $1.6M | 10.1M |
| 2023-03-10 | Klompas Neil A | President & COO | Sell | 3K | $7.83 | $23K | 17K |
| 2023-03-10 | Klompas Neil A | President & COO | Exercise or conversion | 3K | $0.00 | $0 | 17K |
| 2023-03-10 | Klompas Neil A | President & COO | Exercise or conversion | 3K | $0.00 | $0 | 20K |
| 2023-01-20 | EcoR1 Capital, LLC | TenPercentOwner | Buy | 163K | $9.88 | $1.6M | 9.9M |
| 2023-01-19 | EcoR1 Capital, LLC | TenPercentOwner | Buy | 144K | $9.49 | $1.4M | 9.7M |
| 2023-01-18 | EcoR1 Capital, LLC | TenPercentOwner | Buy | 203K | $10.00 | $2.0M | 9.6M |
| 2023-01-17 | EcoR1 Capital, LLC | TenPercentOwner | Buy | 440K | $9.80 | $4.3M | 9.4M |
| 2023-01-13 | EcoR1 Capital, LLC | TenPercentOwner | Buy | 342K | $9.81 | $3.4M | 8.9M |
| 2023-01-11 | EcoR1 Capital, LLC | TenPercentOwner | Buy | 106K | $7.87 | $837K | 8.6M |
| 2023-01-10 | EcoR1 Capital, LLC | TenPercentOwner | Buy | 920K | $7.65 | $7.0M | 8.5M |
| 2022-12-12 | Astle Christopher | SVP & Chief Financial Officer | Exercise or conversion | 2K | $0.00 | $0 | 2K |
| 2022-12-12 | Astle Christopher | SVP & Chief Financial Officer | Sell | 887 | $6.01 | $5K | 1K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON14 Form 144 notices on file for ZYME worth $20.1M at the prices reported; 0 in the last 90 days worth $0. Latest: Jeffrey T L Smith filed on 2026-03-06 to sell 247,333 shares ($6.1M) from 2026-03-06.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-03-06 | Jeffrey T L SmithFormer Officer | 247K | $6.1M | 0.335% | 2026-03-06 | Morgan Stanley Wealth Management Canada |
| 2026-02-17 | Leone D PattersonFormer officer | 32K | $715K | 0.042% | 2026-02-17 | Morgan Stanley Smith Barney |
| 2026-02-13 | Leone D PattersonFormer officer | 129K | $3.0M | 0.172% | 2026-02-13 | Morgan Stanley Smith Barney |
| 2026-01-12 | Jeffrey T L SmithOfficer | 9K | $216K | 0.012% | 2026-01-12 | Morgan Stanley Wealth Management Canada |
| 2026-01-12 | Leone D PattersonFormer officer | 7K | $158K | 0.009% | 2026-01-12 | Morgan Stanley Wealth Management Canada |
| 2026-01-12 | Paul Andrew MooreOfficer | 10K | $222K | 0.013% | 2026-01-12 | Morgan Stanley Wealth Management Canada |
| 2026-01-12 | Mark HollywoodOfficer | 6K | $142K | 0.008% | 2026-01-12 | Morgan Stanley Wealth Management Canada |
| 2026-01-12 | Kenneth GalbraithOfficer, Director | 30K | $705K | 0.041% | 2026-01-12 | Morgan Stanley Wealth Management Canada |
| 2026-01-05 | Smith Jeffrey T LOfficer | 11K | $281K | 0.014% | 2026-01-05 | Morgan Stanley Wealth Management Canada |
| 2026-01-05 | Paul Andrew MooreOfficer | 20K | $535K | 0.027% | 2026-01-05 | Morgan Stanley Wealth Management Canada |
| 2026-01-05 | Kenneth GalbraithOfficer, Director | 54K | $1.4M | 0.073% | 2026-01-05 | Morgan Stanley Wealth Management Canada |
| 2025-12-22 | Galbraith, KennethOfficer, Director | 48K | $1.3M | 0.064% | 2025-12-22 | Morgan Stanley Wealth Management Canada |
| 2025-11-24 | Derek John Michael MillerFormer Director | 118K | $2.8M | 0.158% | 2025-11-24 | Morgan Stanley Smith Barney |
| 2025-11-21 | Neil GallagherFormer Director | 105K | $2.5M | 0.140% | 2025-11-21 | Morgan Stanley Smith Barney |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON11 holders report 5% or more of ZYME in their latest filing, 3 on Schedule 13D (active intent). The largest reported stake is EcoR1 Capital, LLC at 30.7% of the class (22,970,388 shares), filed 2025-11-19 for an event on 2025-11-16.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-05-15 | 13G/Ano. 2 | Rubric Capital Management LPinvestment adviser, partnership | 7.0M | 9.5% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 2 | David Rosenparent holding company, individual | 7.0M | 9.5% | 2026-03-31 |
| 2026-04-15 | 13G | Perceptive Advisors LLCinvestment adviser | 4.0M | 5.4% | 2026-04-08 |
| 2026-04-15 | 13G | Joseph Edelmanindividual | 4.0M | 5.4% | 2026-04-08 |
| 2026-04-15 | 13G | Perceptive Life Sciences Master Fund, Ltd.corporation | 4.0M | 5.4% | 2026-04-08 |
| 2026-02-12 | 13G/Ano. 3 | Morgan Stanleyparent holding company, corporation | 2.5M | 3.4% | 2025-12-31 |
| 2025-11-19 | 13D/Ano. 7 | EcoR1 Capital, LLCinvestment adviser, other entity | 23.0M | 30.7% | 2025-11-16 |
| 2025-11-19 | 13D/Ano. 7 | Oleg Nodelmanindividual, parent holding company | 23.0M | 30.7% | 2025-11-16 |
| 2025-11-19 | 13D/Ano. 7 | EcoR1 Capital Fund Qualified, L.P.partnership | 21.6M | 28.8% | 2025-11-16 |
| 2025-11-14 | 13G/Ano. 6 | Jeremy C. Greenparent holding company, individual | 3.7M | 4.9% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 6 | Redmile Group, LLCinvestment adviser, other entity | 3.7M | 4.9% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | BVF INC/ILcorporation | 3.9M | 5.2% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | LAMPERT MARK Nindividual | 3.9M | 5.2% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | BVF PARTNERS L P/ILinvestment adviser, partnership | 3.9M | 5.2% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | BVF GP HOLDINGS LLCother entity | 3.6M | 4.9% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | BIOTECHNOLOGY VALUE FUND L Ppartnership | 2.0M | 2.7% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | BVF I GP LLCother entity | 2.0M | 2.7% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | BVF II GP LLCother entity | 1.6M | 2.1% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | BIOTECHNOLOGY VALUE FUND II LPpartnership | 1.6M | 2.1% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | Biotechnology Value Trading Fund OS LPpartnership | 213K | 0.3% | 2025-09-30 |
| 2025-11-14 | 13G/Ano. 2 | BVF Partners OS Ltd.corporation | 213K | 0.3% | 2025-09-30 |
13F holders
Tracked managers holding ZYME at their latest 13F. JSON5 of the 30 tracked managers held ZYME at their latest 13F, $34.3M in total at quarter-end prices. Citadel Advisors is the largest at $23.9M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Citadel Advisors | 2026-06-30 | 914K | $23.9M | 0.00% | -236K |
| D. E. Shaw & Co. | 2026-06-30 | 145K | $3.8M | 0.00% | -91K |
| AQR Capital Management | 2026-06-30 | 111K | $2.9M | 0.00% | +21K |
| Two Sigma Investments | 2026-06-30 | 72K | $1.9M | 0.00% | new |
| Fisher Asset Management | 2026-06-30 | 71K | $1.9M | 0.00% | -31K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Zymeworks in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Zymeworks (ZYME), SEC CIK 1937653, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-06.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-03-06.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-05-15.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-09.JSON and CSV
- Company record
- EDGAR filing index for CIK 1937653Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of ZYME is sold short?
5,577,540 shares were held short at the 2026-10-15 settlement, 4.4 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is ZYME's daily short volume?
On 2026-11-02, 224,569 of the 298,460 ZYME shares reported to FINRA were sold short, 75.2% of the day's reported volume. Short volume is a flow for one day, not a position.
Does ZYME have fails to deliver?
The SEC's latest file shows 1,120 ZYME shares failed to deliver at settlement 2026-10-06. Fails are reported per settlement date and published twice a month with a lag.
Are ZYME insiders buying or selling?
Insiders at ZYME reported 1 open-market sell worth $358K in the last 90 days and no open-market buys. Latest filing: Schayowitz Adam (EVP, Head of R&D) on 2026-10-09.
Have ZYME insiders filed to sell?
14 Form 144 notices on file for ZYME worth $20.1M at the prices reported; 0 in the last 90 days worth $0. Latest: Jeffrey T L Smith filed on 2026-03-06 to sell 247,333 shares ($6.1M) from 2026-03-06.
Who owns 5% or more of ZYME?
11 holders report 5% or more of ZYME in their latest filing, 3 on Schedule 13D (active intent). The largest reported stake is EcoR1 Capital, LLC at 30.7% of the class (22,970,388 shares), filed 2025-11-19 for an event on 2025-11-16.
Which tracked 13F managers own ZYME?
5 of the 30 tracked 13F managers held ZYME shares at their latest filing, $34.3M in all. The largest: Ken Griffin's Citadel Advisors (914K shares, $23.9M), D. E. Shaw & Co. (145K shares, $3.8M), Cliff Asness's AQR Capital Management (111K shares, $2.9M), Two Sigma Investments (72K shares, $1.9M), Ken Fisher's Fisher Asset Management (71K shares, $1.9M).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.